Protein / target

Sodium channel protein type 3 subunit alpha

SCN3AQ9NY46Homo sapiensSwiss-Prot
Clinically validated
Therapeutic maturity
59
Approved medicines
30
Clinical trials
Small-molecule tractable
Druggability
Approved Drug

Protein at a glance

Biological role

Voltage-gated sodium channel activity

Primary system

Endocrine & metabolic

Strongest disease association

developmental and epileptic encephalopathy, 62

Genetic evidence · score 0.89

Therapeutic maturity

Clinically validated target

59 approved medicines against this target

Druggability

Small molecule

Open Targets tractability · Approved Drug

Clinical development

59 approved · 10 in clinical development

30 linked trials

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function

Pore-forming subunit of Nav1.3, a voltage-gated sodium (Nav) channel that directly mediates the depolarizing phase of action potentials in excitable membranes. Navs, also called VGSCs (voltage-gated sodium channels) or VDSCs (voltage-dependent sodium channels), operate by switching between closed and open conformations depending on the voltage difference across the membrane. In the open conformation they allow Na(+) ions to selectively pass through the pore, along their electrochemical gradient. The influx of Na+ ions provokes membrane depolarization, initiating the propagation of electrical signals throughout cells and tissues (PubMed:24157691, PubMed:28235671, PubMed:29466837, PubMed:35277491). In some secretory cell types, it also participates in cell excitability through membrane depolarization and regulates cells responsiveness to stimuli triggering secretion. For instance, it controls the release of serotonin/5-hydroxytryptamine by enterochromaffin cells and is required for both glucagon- and glucose-induced insulin secretion in pancreatic endocrine cells (By similarity)

Subcellular location

Cell membraneBasal cell membrane
Domains and Gene Ontology detail (11)

Domains & features

IQ

Gene Ontology

  • Cbasal plasma membrane
  • Ccytoplasm
  • Cplasma membrane
  • Cvoltage-gated sodium channel complex
  • Fvoltage-gated sodium channel activity
  • Pbehavioral response to pain
  • Pcardiac muscle cell action potential involved in contraction
  • Pmembrane depolarization during action potential
  • Psodium ion transmembrane transport
  • Psodium ion transport

2000 aa · 226 kDa · 4 isoforms

Biological roles

Reactome v97

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Ion channel gatingGOImmune signallingUniProt
View supporting evidence

Ion channel gating

  • ·sodium ion transmembrane transport

Immune signalling

  • ·Pore-forming subunit of Nav1.3, a voltage-gated sodium (Nav) channel that directly media…
View underlying pathways (3)

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Interaction neighbourhood

STRING v12.0

Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.

SCN1BSCN2BSCN2ASCN9ACALHM1SCN4BSCN4ASCN3BNAV1FGF13SCN3A

10 strongest partners — larger node and heavier line mean higher confidence

Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.

Drugs targeting this protein

2

Whether each drug engages this protein directly or through a complex, and how many other targets are recorded for it. Direct binders with few recorded targets are listed first.

Riluzole
ApprovedBlocker

Sodium channel alpha subunit blocker

Appears in clinical studies involving amyotrophic lateral sclerosis, progressive supranuclear palsy, multiple system atrophy, Huntington disease

Acts on a complex — shared with SCN5A, SCN4A, SCN7A +6 more · 1 of 10 recorded protein targets — broad pharmacology

lamotrigine
ApprovedBlocker

Sodium channel alpha subunit blocker

Appears in clinical studies involving epilepsy, bipolar disorder, major depressive disorder, Seizure

Acts on a complex — shared with SCN5A, SCN4A, SCN7A +6 more · 1 of 10 recorded protein targets — broad pharmacology

ChEMBL mechanism, action type and target identity. Open Targets clinical status and indications.

Translational evidence

Open Targets 26

Why this target matters therapeutically — disease associations, drugs in development, tractability and safety, from Open Targets.

Strongest genetic associations

Human genetic evidence — the most direct causal link between this target and a disease.

developmental and epileptic encephalopathy, 620.89

Genetic · overall 0.76

familial focal epilepsy with variable foci0.87

Genetic · overall 0.77

Seizure0.74

Genetic · overall 0.72

epilepsy0.67

Genetic · overall 0.75

focal epilepsy0.61

Genetic literature · overall 0.73

Highest-confidence therapeutic associations

Diseases where a drug acting on this target has already reached clinical development.

Pain0.99

Clinical · overall 0.61

bipolar disorder0.99

Clinical · overall 0.60

major depressive disorder0.98

Clinical · overall 0.60

Pruritus0.97

Clinical · overall 0.59

migraine disorder0.97

Clinical · overall 0.59

Show all associations
familial focal epilepsy with variable foci0.77
developmental and epileptic encephalopathy, 620.76
epilepsy0.75
focal epilepsy0.73
Seizure0.72
Pain0.61
bipolar disorder0.60
major depressive disorder0.60
Pruritus0.59
migraine disorder0.59

Open Targets ranks 544 associations for this target and we store the top 10 by aggregated score. The long tail is largely literature co-mention and RNA-expression evidence, not evidence that this target drives those diseases.

Known drugs · 73 total

PRILOCAINEApproval

Pain · physiological sexual disorder · cesarean section

QUINIDINE GLUCONATEApproval

Ventricular arrhythmia · malaria

TETRACAINEApproval

Pain · hemorrhoid · Pruritus

INDECAINIDEApproval
FOSPHENYTOIN SODIUMApproval
PROCAINEApproval

hemorrhoid · osteoarthritis · acute kidney injury

OXCARBAZEPINEApproval

epilepsy · Seizure · Seizure

PRILOCAINE HYDROCHLORIDEUnknown

frozen shoulder

RUFINAMIDEApproval

Seizure · Lennox-Gastaut syndrome · Lennox-Gastaut syndrome

MEPIVACAINE HYDROCHLORIDEPhase 3

Pain · diabetes mellitus

Tractability

SM · Approved DrugSM · Structure with LigandSM · High-Quality LigandSM · Druggable FamilyAB · UniProt loc high confAB · GO CC high confAB · UniProt loc med confAB · UniProt SigP or TMHMMPR · UniProt UbiquitinationPR · Database UbiquitinationPR · Half-life DataPR · Small Molecule Binder

Clinical trials

30

Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein.

Show remaining trials (24)

COMPLETED · via lamotrigine · NCT01463111

TERMINATED · via lamotrigine · NCT01891890

COMPLETED · via lamotrigine · NCT00088452

COMPLETED · via lamotrigine · NCT00513019

TERMINATED · via Riluzole · NCT01703039

COMPLETED · via lamotrigine · NCT00516139

ClinicalTrials.gov via the drug-target graph.

Forefront confidence

Synthesis

Our own weighting of the evidence behind each disease association. Human genetics and clinical evidence count for most; literature co-mention counts for little, because two entities sharing an abstract is not evidence that one drives the other.

SeizureWell supported
0.93
agreement 0.831.00
Clinical50%Genetic50%Literature0%

Open Targets aggregate 0.72 · 3 independent evidence families

epilepsyWell supported
0.92
agreement 0.811.00
Clinical51%Genetic46%Literature3%Genetic literaturedup

Open Targets aggregate 0.75 · 3 independent evidence families · 1 not counted as duplicate

developmental and epileptic encephalopathy, 62Well supported
0.89
agreement 0.771.00
Genetic100%Genetic literaturedup

Open Targets aggregate 0.76 · 1 independent evidence family · 1 not counted as duplicate

familial focal epilepsy with variable fociWell supported
0.87
agreement 0.731.00
Genetic100%Literature0%Genetic literaturedup

Open Targets aggregate 0.77 · 2 independent evidence families · 1 not counted as duplicate

focal epilepsyWell supported
0.86
agreement 0.750.98
Clinical59%Genetic literature40%Literature1%

Open Targets aggregate 0.73 · 3 independent evidence families

This ranking differs from Open Targets' own: re-weighting moves genetically-evidenced diseases above more heavily co-mentioned ones. The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the underlying per-type scores are shown above so the calculation can be checked.

What's happening now

60

Recent activity around this target, drawn from one canonical event stream. Every item is reached through 2 drugs that target this protein, so each event is news about that drug rather than about the protein directly.

  1. Label change2026-07-27

    Label change: LAMOTRIGINE (ANDA206382)

    fda · regulatory · fda · via lamotrigine

  2. Label change2026-07-17

    Label change: LAMOTRIGINE (NDA218879)

    fda · regulatory · fda · via lamotrigine

  3. Label change2026-07-17

    Label change: LAMOTRIGINE (NDA218879)

    fda · regulatory · fda · via lamotrigine

  4. Label change2026-07-13

    Label change: LAMOTRIGINE (ANDA219677)

    fda · regulatory · fda · via lamotrigine

  5. Label change2026-06-26

    Label change: LAMOTRIGINE (ANDA204158)

    fda · regulatory · fda · via lamotrigine

  6. Label change2026-06-26

    Label change: LAMOTRIGINE (ANDA204158)

    fda · regulatory · fda · via lamotrigine

  7. Label change2026-06-26

    Label change: LAMOTRIGINE (ANDA204158)

    fda · regulatory · fda · via lamotrigine

  8. Label change2026-06-26

    Label change: LAMOTRIGINE (ANDA204158)

    fda · regulatory · fda · via lamotrigine

  9. Label change2025-12-31

    Label change: LAMOTRIGINE (ANDA090401)

    fda · regulatory · fda · via lamotrigine

  10. Label change2025-10-10

    Label change: LAMOTRIGINE (NDA022251)

    fda · regulatory · fda · via lamotrigine

  11. Label change2025-10-10

    Label change: LAMOTRIGINE (NDA022251)

    fda · regulatory · fda · via lamotrigine

  12. Regulatory approval2025-10-07

    Approval: LAMOTRIGINE (ANDA219677)

    fda · regulatory · fda · via lamotrigine

Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.